Research in Stroke

Ethnic/Racial Variations of Intracerebral Hemorrhage (ERICH)
 
Site Principal Investigator: Bruce Coull, MD   
Contact: Eddie Soto, Research Specialist, 520-626-3576
 
Funded By: The National Institute of Neurological Disorders and Stroke (NINDS) 
 
Purpose: ERICH is an NIH-funded, multi-center, prospective study designed to identify racial and ethnic risk factors (including genetic variations) for intracerebral hemorrhage (ICH).
 
Eligibility Criteria:
  • Age 18 years old or older
  • Spontaneous ICH within 3 months
  • Resides within 50 miles of a recruiting center for at least 6 months
________________________________________
 
MR WITNESS: A Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients
 
Site Principal Investigator: Kendra Drake, MD
Contact: Eddie Soto, Research Specialist, 520-626-3576
 
Funded By: The National Institute of Neurological Disorders and Stroke (NINDS) 
 
Purpose:  The goal of this study is to determine the safety of extending intravenous alteplase treatment to acute stroke subjects with unclear onsets who are evaluated within 24 hours from last known well and who can be treated within 4.5 hours from "symptom discovery" who present with an MRI pattern consistent with early stage stroke. MR WITNESS is a multi-center, open-label, single-arm, Phase IIa safety study. 
 
Eligibility Criteria: 
  • Adult male and female patients with acute ischemic stroke age 18-85
  • Stroke symptoms within 24 hours of triage
________________________________________
 
Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial
 
Site Principal Investigator: Kendra Drake, MD
Contact: Eddie Soto, Research Specialist, 520-626-3576
 
Funded By: University of California, San Francisco and the Neurological Emergencies Treatment Trials Network (NETT)
 
Purpose:  The primary objective is to determine whether clopidogrel 75 mg/day by mouth after a loading dose of 600 mg of clopidogrel is effective in preventing major ischemic vascular events (ischemic stroke, myocardial infarction, and ischemic vascular death) at 90 days when initiated within 12 hours of TIA or minor ischemic stroke onset in patients receiving aspirin 50-325 mg/day (with a dose of 150-200 mg daily for 5 days followed by 75-100 mg daily strongly recommended).
 
Eligibility Criteria: 
  • Neurological deficit (based on history or exam) attributed to focal brain ischemia and EITHER:
    • High risk TIA: OR
    • Minor ischemic stroke
  • Ability to randomize within 12 hours of time last known free of new ischemic symptoms
  • Head CT or MRI ruling out hemorrhage or other pathology
  • Ability to tolerate aspirin at a dose of 50-325 mg/day
________________________________________
 
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial
 
Site Principal Investigator: Kendra Drake, MD
Contact:  Eddie Soto, Research Specialist, 520-626-3576
 
Funded By: The National Institute of Neurological Disorders and Stroke (NINDS) and the Neurological Emergencies Treatment Trials (NETT) 
 
Purpose:  The purpose of the SHINE trial is to determine if treatment with an insulin protocol that maintains euglycemia (normal blood sugars) for 3 days in hyperglycemic acute ischemic stroke patients will improve clinical outcome and be safe.
 
Eligibility Criteria: 
  • Age 18 years or older
  • Clinical diagnosis of ischemic stroke defined as acute neurological deficit occurring in one or more cerebral vascular territories
  • Protocol treatment must begin within 12 hours after stroke symptom onset 
  • Known history of type 2 diabetes mellitus and glucose >110 mg/dL OR admission blood glucose ≥150 mg/dL in those w/o known diabetes mellitus
________________________________________
 
SOCRATES:   A Randomized, Double-Blind, Multinational Study to Prevent Major Vascular Events With Ticagrelor Compared to Aspirin (ASA) in Patients With Acute Ischemic Stroke or TIA
 
Site Principal Investigator: Bruce Coull, MD
Contact:  Eddie Soto, Research Specialist, 520-626-3576
 
Funded By: AstraZeneca 
 
Purpose: The goal of SOCRATES is to compare the effect of 90 day treatment with ticagrelor (180 mg) followed by 90 mg twice daily maintenance dose vs acetylsalicylic acid aspirin (300 mg) followed by 100 mg once daily maintenance dose for the prevention of major vascular events in patients with acute ischemic stroke or transient ischemic attack (TIA).
 
Eligibility Criteria: 
  • Men or women 40 years of age or older
  • Either acute ischemic stroke or high-risk TIA as defined here and randomization occurring within 24 hours after onset of symptoms
________________________________________
 
GAMES:   A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
 
Site Principal Investigator:  Kendra Drake, MD 
Contact:  Eddie Soto, Research Specialist, 520-626-3576
 
Funded By: Remedy Pharmaceuticals 
 
Purpose: The goal of this study is to demonstrate the efficacy of RP-1127 compared to placebo in subjects with a severe anterior circulation ischemic stroke who are likely to develop malignant edema. 
 
Eligibility Criteria: 
  • Men or women between the ages of 18-80 
  • Must have a clinical diagnosis of acute severe anterior circulation ischemic stroke

________________________________________

ATACH II: Antihypertensive Treatment of Acute Cerebral Hemorrhage

Site Principal Investigator:  Chelsea Kidwell, MD
Contact: Eddie Soto, Research Specialist, 520-626-3576
 
Funded by: National Institutes of Health
 
Purpose: The goal of this study is to determine the therapeutic benefit of intensive SBP treatment (SBP < 140mmHg) compared to standard SBP treatment (SBP < 180 mmHg) in patients with ICH.
 
Eligibility Criteria:
  • Age 18 years old or older
  • IV Nicardipine can be initiated within 4.5 hours of onset
  • ICH < 60 cc
  • GCS of at least 5